Fidelity Investments
TAK icon

Fidelity Investments’s Takeda Pharmaceutical TAK Stock Holding History

Fidelity Investments’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132M Buy
7,117,486
+3,060,618
+75% +$53.7M 0.01% 1049
2025
Q4 		$63.2M Sell
4,056,868
-130,078
-3% -$1.86M ﹤0.01% 1345
2025
Q3 		$61.3M Buy
4,186,946
+85,285
+2% +$1.27M ﹤0.01% 1370
2025
Q2 		$63.4M Buy
4,101,661
+236,563
+6% +$3.5M ﹤0.01% 1299
2025
Q1 		$57.5M Buy
3,865,098
+478,810
+14% +$6.71M ﹤0.01% 1302
2024
Q4 		$44.8M Buy
3,386,288
+477,370
+16% +$6.56M ﹤0.01% 1424
2024
Q3 		$41.4M Buy
2,908,918
+286,052
+11% +$4.06M ﹤0.01% 1454
2024
Q2 		$33.9M Buy
2,622,866
+48,626
+2% +$644K ﹤0.01% 1464
2024
Q1 		$35.8M Buy
2,574,240
+395,850
+18% +$5.76M ﹤0.01% 1455
2023
Q4 		$31.1M Sell
2,178,390
-414,960
-16% -$5.89M ﹤0.01% 1471
2023
Q3 		$40.1M Buy
2,593,350
+115,947
+5% +$1.79M ﹤0.01% 1326
2023
Q2 		$38.9M Sell
2,477,403
-15,618
-0.6% -$256K ﹤0.01% 1366
2023
Q1 		$41.1M Buy
2,493,021
+189,141
+8% +$3.01M ﹤0.01% 1330
2022
Q4 		$35.9M Buy
2,303,880
+293,970
+15% +$4.11M ﹤0.01% 1391
2022
Q3 		$26.1M Buy
2,009,910
+155,918
+8% +$2.17M ﹤0.01% 1520
2022
Q2 		$26M Sell
1,853,992
-594,212
-24% -$8.48M ﹤0.01% 1546
2022
Q1 		$35.1M Buy
2,448,204
+525,999
+27% +$7.72M ﹤0.01% 1546
2021
Q4 		$26.2M Buy
1,922,205
+144,880
+8% +$2.03M ﹤0.01% 1695
2021
Q3 		$29.1M Buy
1,777,325
+219,185
+14% +$3.68M ﹤0.01% 1663
2021
Q2 		$26.2M Buy
1,558,140
+271,764
+21% +$4.63M ﹤0.01% 1727
2021
Q1 		$23.5M Buy
1,286,376
+330,353
+35% +$5.94M ﹤0.01% 1738
2020
Q4 		$17.4M Buy
956,023
+10,129
+1% +$178K ﹤0.01% 1772
2020
Q3 		$16.9M Sell
945,894
-42,592
-4% -$776K ﹤0.01% 1633
2020
Q2 		$17.7M Buy
988,486
+104,692
+12% +$1.88M ﹤0.01% 1600
2020
Q1 		$13.4M Buy
883,794
+328,184
+59% +$5.95M ﹤0.01% 1584
2019
Q4 		$11M Sell
555,610
-49,384
-8% -$945K ﹤0.01% 1813
2019
Q3 		$10.4M Sell
604,994
-2,103,312
-78% -$36.4M ﹤0.01% 1811
2019
Q2 		$47.9M Sell
2,708,306
-4,854,953
-64% -$88.3M 0.01% 1239
2019
Q1 		$154M Buy
7,563,259
+7,563,179
+9,453,974% +$152M 0.02% 737
2018
Q4 		$1K Buy
+80
New +$1.35K ﹤0.01% 3425

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments's TAK Position: Q1 2026 in Review

Fidelity Investments increased its Takeda Pharmaceutical (TAK) stake by 75% in Q1 2026, buying an estimated $53.7M and bringing the position to 7,117,486 shares worth $132M. The position accounts for 0.01% of the portfolio, ranked #1049.

Fidelity Investments first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $154M in Q1 2019. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Fidelity Investments held 7,117,486 shares of Takeda Pharmaceutical worth $132M as of Q1 2026.
  • Fidelity Investments bought 3,060,618 Takeda Pharmaceutical shares in Q1 2026, an estimated $53.7M.
  • Takeda Pharmaceutical made up 0.01% of Fidelity Investments's portfolio in Q1 2026, its #1049 holding.
  • Fidelity Investments first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
  • Fidelity Investments's Takeda Pharmaceutical position peaked at $154M in Q1 2019.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.